Adherence/Retention Alzheimer's Prevention Initiative Colombia Plan

Alzheimer's and Dementia: Translational Research and Clinical Interventions - Tập 4 - Trang 283-287 - 2018
Silvia Rios-Romenets1, Natalia Acosta-Baena1, Liliana Lopez1, Lucia Madrigal-Zapata1, Helen Street2, Laura Jakimovich2, Jessica B. Langbaum2, William Cho3, Eric M. Reiman2, Pierre N. Tariot2, Francisco Lopera1
1Grupo de Neurociencias, Universidad de Antioquia, SIU, Medellín, Colombia
2Banner Alzheimer's Institute, Phoenix, AZ, USA
3Genentech, a Member of the Roche Group, South San Francisco, CA, USA

Tóm tắt

AbstractIntroductionThe Alzheimer's Prevention Initiative Colombia Trial is a collaborative project involving the Neurosciences Group of Antioquia, Genentech/Roche, and the Banner Alzheimer's Institute, studying whether crenezumab can delay or prevent the clinical onset of Alzheimer's disease in cognitively unimpaired individuals who carry the PSEN1 E280A mutation. In an effort to optimize participant compliance and adherence and maintain interest in the trial for its duration, the Neurosciences Group of Antioquia developed an “Adherence/Retention Plan.” This plan identifies potential barriers to trial adherence related to characteristics of the participants and study partners, protocol design, sponsors, investigators, environmental factors, and characteristics of this population in general and identifies potential solutions to these barriers.MethodsNeurosciences Group of Antioquia designed and implemented a number of strategies including a) a prescreening process that emphasized detailed and staged informed consent involving the participant and family and/or friends, b) a schedule of visits and assessments designed to minimize burden while achieving the trial's aims, c) appointment reminders, d) reimbursement for transportation and missed work, e) meals during study visits, f) birthday cards, g) quarterly newsletters, h) annual in‐person feedback meetings, i) a supplemental health plan to participants, and j) a social plan to support family members. All the methods used in this plan were approved by local ethics committees.ResultsBy the end of the fourth year of the trial, participant retention was 94.0%, with most participants reporting that they felt “very satisfied” with their participation in the trial.DiscussionThe Adherence/Retention Plan plays a crucial role in maintaining adherence and compliance needed to achieve the ambitious goals of the Alzheimer's Prevention Initiative‐Colombia Autosomal Dominant Alzheimer's Disease Trial and may offer guideposts for other prevention trials.

Tài liệu tham khảo

Knebl J.A., 2010, Recruitment of subjects into clinical trials for Alzheimer disease, J Am Osteopath Assoc, 110, S43 DeKosky S.T., 2006, Maintaining adherence and retention in dementia prevention trials, Neurology, 67, S14, 10.1212/WNL.67.9_suppl_3.S14 10.1111/j.1365-2702.2009.03041.x 10.1016/j.cct.2004.11.015 10.1016/j.neurol.2013.07.017 10.3233/JAD-2011-0059 10.1126/scitranslmed.3007941 10.1038/nrneurol.2015.177 Peterson R.C., 2016, Barriers for prevention and prodromal AD trials, J Prev Alz Dis, 3, 66 10.1038/srep39374 10.1523/JNEUROSCI.4742-11.2012 10.1016/j.trci.2018.02.002 Martin L.R., 2005, The challenge of patient adherence, Ther Clin Risk Manag, 1, 189 10.1016/S0197-2456(98)00005-1 Rios‐Romenets S., 2018, The value of pre‐screening in the Alzheimer's Prevention Initiative (API) Autosomal Dominant Alzheimer's Disease Trial, J Prev Alzheimers Dis, 5, 49 Ospina Lopera P., 2016, Psychosocial and education programs for families with neurodegenerative diseases in Antioquia, Colombia: The Neuroscience Group of Antioquia Social Plan (abstract P2–369), Alzheimers Dement, 12, 786
Thông tin
Thông tin xuất bản

Alzheimer's and Dementia: Translational Research and Clinical Interventions

Tập 4

283-287

Thông tin tác giả